<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script src="/scripts/https-redirect.js"></script>
<meta http-equiv="Content-Security-Policy" content="upgrade-insecure-requests">
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>FDA Kopya GLP-1 Ä°laÃ§larÄ±na SavaÅŸ AÃ§tÄ±: Compounding Krizi | UzunYaÅŸa</title>
<meta name="description" content="FDA, compounding eczanelerinin Ã¼rettiÄŸi kopya semaglutid Ã¼rÃ¼nlerini yasaklÄ±yor. Hims 49 dolarlÄ±k GLP-1 hapÄ±nÄ± geri Ã§ekti. Kopya ilaÃ§larÄ±n riskleri ve TÃ¼rkiye'deki durum.">
<meta name="author" content="UzunYaÅŸa">
<link rel="canonical" href="https://uzunyasa.com/pages/blog/fda-kopya-glp1-yasaklari.html">
<!-- Open Graph -->
<meta property="og:title" content="FDA Kopya GLP-1 Ä°laÃ§larÄ±na SavaÅŸ AÃ§tÄ± | UzunYaÅŸa">
<meta property="og:description" content="FDA, compounding eczanelerinin Ã¼rettiÄŸi kopya semaglutid Ã¼rÃ¼nlerini yasaklÄ±yor. Hims 49 dolarlÄ±k GLP-1 hapÄ±nÄ± geri Ã§ekti.">
<meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
<meta property="og:url" content="https://uzunyasa.com/pages/blog/fda-kopya-glp1-yasaklari.html">
<meta property="og:type" content="article">
<meta property="og:locale" content="tr_TR">
<meta property="article:published_time" content="2026-02-09">
<!-- Fonts -->
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800&family=Playfair+Display:wght@400;500;600;700&display=swap" rel="stylesheet">
<!-- Styles -->
<link rel="stylesheet" href="../../styles/main.css">
<link rel="stylesheet" href="../../styles/content-page.css">
<link rel="stylesheet" href="../../styles/animations.css">
<style>
/* ===== READING PROGRESS BAR ===== */
.blog-progress {
  position: fixed; top: 0; left: 0; width: 0%;
  height: 3px; z-index: 10001;
  background: linear-gradient(90deg, #0D7377, #14919B, #E8963E);
  transition: width 0.1s linear;
}

/* ===== BLOG HERO ===== */
.blog-hero {
  position: relative;
  min-height: 480px;
  display: flex;
  align-items: flex-end;
  overflow: hidden;
  margin-top: 70px;
}
.blog-hero-img {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  object-fit: cover;
}
.blog-hero-overlay {
  position: absolute; top: 0; left: 0; width: 100%; height: 100%;
  background: linear-gradient(180deg,
    rgba(25,81,87,0.3) 0%,
    rgba(25,81,87,0.55) 40%,
    rgba(15,61,66,0.88) 100%);
}
.blog-hero-content {
  position: relative; z-index: 2;
  max-width: 860px; margin: 0 auto;
  padding: 3rem 2rem 3.5rem;
  color: white;
}
.blog-hero-badge {
  display: inline-block;
  padding: 0.4rem 1rem;
  border-radius: 20px;
  font-size: 0.8rem; font-weight: 600;
  margin-bottom: 1.25rem;
  background: #EC4899;
  color: white;
}
.blog-hero-title {
  font-family: 'Playfair Display', serif;
  font-size: clamp(2rem, 4vw, 2.8rem);
  font-weight: 600;
  line-height: 1.2;
  margin-bottom: 1rem;
  text-shadow: 0 2px 8px rgba(0,0,0,0.3);
}
.blog-hero-subtitle {
  font-size: 1.15rem;
  opacity: 0.9;
  max-width: 640px;
  line-height: 1.7;
  margin-bottom: 1.25rem;
}
.blog-hero-meta {
  display: flex; gap: 1.5rem; flex-wrap: wrap;
  font-size: 0.85rem; opacity: 0.8;
}
.blog-hero-meta span { display: flex; align-items: center; gap: 0.4rem; }

/* ===== ARTICLE BODY ===== */
.blog-article {
  max-width: 800px;
  margin: 0 auto;
  padding: 2.5rem 2rem 4rem;
}

/* ===== BREADCRUMB ===== */
.blog-breadcrumb {
  display: flex; align-items: center; gap: 0.5rem;
  font-size: 0.85rem; color: var(--text-light);
  margin-bottom: 2rem; flex-wrap: wrap;
}
.blog-breadcrumb a {
  color: var(--primary); text-decoration: none; font-weight: 500;
}
.blog-breadcrumb a:hover { text-decoration: underline; }

/* ===== TOC ===== */
.blog-toc {
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border: 1px solid #e2e8f0;
  border-left: 4px solid var(--primary);
  border-radius: 0 16px 16px 0;
  padding: 1.75rem 2rem;
  margin-bottom: 2.5rem;
}
.blog-toc h4 {
  font-size: 0.9rem; font-weight: 700;
  text-transform: uppercase; letter-spacing: 0.06em;
  color: var(--primary); margin-bottom: 1rem;
}
.blog-toc ol {
  list-style: none; counter-reset: toc; margin: 0; padding: 0;
}
.blog-toc li { counter-increment: toc; margin-bottom: 0.4rem; }
.blog-toc li a {
  display: flex; align-items: center; gap: 0.6rem;
  text-decoration: none; color: #334155;
  font-size: 0.95rem; padding: 0.4rem 0.6rem;
  border-radius: 8px; transition: all 0.2s;
}
.blog-toc li a::before {
  content: counter(toc);
  display: inline-flex; align-items: center; justify-content: center;
  width: 26px; height: 26px;
  background: #e2e8f0; border-radius: 50%;
  font-size: 0.75rem; font-weight: 700; color: #475569;
  flex-shrink: 0; transition: all 0.2s;
}
.blog-toc li a:hover { background: rgba(13,115,119,0.08); color: var(--primary); }
.blog-toc li a:hover::before { background: var(--primary); color: white; }

/* ===== CONTENT STYLES ===== */
.blog-content p {
  font-size: 1.05rem; line-height: 1.8; margin-bottom: 1.5rem; color: var(--text-dark);
}
.blog-content h2 {
  font-size: 1.5rem; font-weight: 700; color: var(--primary);
  margin: 3rem 0 1.25rem; padding-top: 2rem;
  border-top: 1px solid var(--border);
  position: relative; padding-bottom: 0.75rem;
}
.blog-content h2::after {
  content: ''; position: absolute; bottom: 0; left: 0;
  width: 60px; height: 3px;
  background: linear-gradient(90deg, var(--primary), #10b981);
  border-radius: 2px;
}
.blog-content h2:first-of-type { border-top: none; padding-top: 0; margin-top: 0; }
.blog-content h3 {
  font-size: 1.2rem; font-weight: 600; margin: 2rem 0 0.75rem; color: var(--text-dark);
}
.blog-content ul, .blog-content ol {
  margin: 1.25rem 0; padding-left: 1.5rem;
}
.blog-content li { margin-bottom: 0.5rem; font-size: 1.02rem; line-height: 1.7; }
.blog-content strong { color: var(--text-dark); }
.blog-content a { color: var(--primary); text-decoration: underline; }

/* ===== INFO BOXES (Premium) ===== */
.blog-box {
  padding: 1.5rem 1.75rem;
  border-radius: 0 14px 14px 0;
  margin: 2rem 0;
  border-left: 4px solid;
  position: relative;
  display: flex; gap: 1rem; align-items: flex-start;
}
.blog-box .box-icon {
  flex-shrink: 0; width: 28px; height: 28px; margin-top: 2px;
}
.blog-box .box-body { flex: 1; }
.blog-box .box-body strong { display: block; margin-bottom: 0.4rem; font-size: 0.95rem; }
.blog-box .box-body p, .blog-box .box-body ul { margin: 0; font-size: 0.95rem; line-height: 1.7; }
.blog-box .box-body ul { padding-left: 1.2rem; margin-top: 0.5rem; }
.blog-box .box-body li { margin-bottom: 0.3rem; }

.blog-box.info {
  background: linear-gradient(135deg, #eff6ff, #f0f9ff);
  border-left-color: #3B82F6;
}
.blog-box.info .box-icon { color: #3B82F6; }
.blog-box.warning {
  background: linear-gradient(135deg, #fef3c7, #fffbeb);
  border-left-color: #F59E0B;
}
.blog-box.warning .box-icon { color: #F59E0B; }
.blog-box.success {
  background: linear-gradient(135deg, #ecfdf5, #f0fdf4);
  border-left-color: #10B981;
}
.blog-box.success .box-icon { color: #10B981; }
.blog-box.danger {
  background: linear-gradient(135deg, #fef2f2, #fee2e2);
  border-left-color: #EF4444;
}
.blog-box.danger .box-icon { color: #EF4444; }
.blog-box.tip {
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
  border-left-color: #0D7377;
}
.blog-box.tip .box-icon { color: #0D7377; }

/* ===== KEY STAT BOX ===== */
.key-stat {
  display: flex; align-items: center; gap: 1.5rem;
  padding: 1.75rem 2rem;
  border-radius: 0 16px 16px 0;
  margin: 2rem 0;
  border-left: 5px solid var(--primary);
  background: linear-gradient(135deg, #f0fdfa, #ecfdf5);
}
.key-stat .ks-num {
  font-size: 2.75rem; font-weight: 800; color: var(--primary);
  line-height: 1; white-space: nowrap;
}
.key-stat .ks-text { font-size: 0.95rem; color: #195157; line-height: 1.6; }
.key-stat.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
.key-stat.accent .ks-num { color: #E8963E; }
.key-stat.danger { border-left-color: #EF4444; background: linear-gradient(135deg, #fef2f2, #fee2e2); }
.key-stat.danger .ks-num { color: #EF4444; }

/* ===== STAT CARDS ===== */
.stat-cards {
  display: grid;
  grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
  gap: 1rem; margin: 2rem 0;
}
.stat-card {
  background: white;
  border: 1px solid var(--border);
  border-radius: 16px;
  padding: 1.5rem;
  text-align: center;
  transition: all 0.3s ease;
  position: relative; overflow: hidden;
}
.stat-card::before {
  content: ''; position: absolute; top: 0; left: 0; right: 0;
  height: 3px;
  background: linear-gradient(90deg, var(--primary), var(--accent));
}
.stat-card:hover { transform: translateY(-4px); box-shadow: 0 12px 30px rgba(0,0,0,0.1); }
.stat-card .sc-num {
  font-size: 2rem; font-weight: 800; color: var(--primary);
  margin-bottom: 0.25rem;
}
.stat-card .sc-label {
  font-size: 0.8rem; color: var(--text-light); line-height: 1.4;
}

/* ===== COMPARISON TABLE ===== */
.blog-table {
  width: 100%; border-collapse: collapse; margin: 2rem 0;
  font-size: 0.95rem; border-radius: 12px; overflow: hidden;
  border: 1px solid var(--border);
}
.blog-table th {
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  padding: 1rem; text-align: left; font-weight: 600;
  color: var(--primary); border-bottom: 2px solid var(--primary);
}
.blog-table td {
  padding: 0.85rem 1rem; border-bottom: 1px solid var(--border);
}
.blog-table tr:hover td { background: rgba(13,115,119,0.03); }
.blog-table tr:last-child td { border-bottom: none; }

/* ===== SVG INFOGRAPHIC ===== */
.blog-infographic {
  margin: 2.5rem 0; padding: 2rem;
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border-radius: 16px;
  border: 1px solid #e2e8f0;
  text-align: center;
}
.blog-infographic svg { max-width: 100%; height: auto; }
.blog-infographic figcaption {
  margin-top: 1rem; font-size: 0.85rem;
  color: var(--text-light); font-style: italic;
}

/* ===== PULL QUOTE ===== */
.blog-quote {
  position: relative;
  padding: 2rem 2.5rem;
  margin: 2.5rem 0;
  font-size: 1.15rem; font-style: italic;
  color: #334155; line-height: 1.7;
  background: linear-gradient(135deg, #f8fafc, #f0f9ff);
  border-radius: 16px;
  border-left: 4px solid var(--primary);
}
.blog-quote::before {
  content: '\201C'; position: absolute; top: -8px; left: 16px;
  font-size: 4rem; color: rgba(13,115,119,0.12);
  font-family: Georgia, serif; line-height: 1;
}
.blog-quote cite {
  display: block; margin-top: 0.75rem;
  font-size: 0.9rem; font-style: normal;
  font-weight: 600; color: var(--primary);
}

/* ===== KEY TAKEAWAY ===== */
.blog-takeaway {
  background: linear-gradient(135deg, #195157, #2a6b73);
  color: white; padding: 2rem; border-radius: 16px;
  margin: 2.5rem 0; position: relative; overflow: hidden;
}
.blog-takeaway::before {
  content: ''; position: absolute; top: -30%; right: -10%;
  width: 200px; height: 200px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-takeaway h4 {
  font-size: 0.85rem; text-transform: uppercase;
  letter-spacing: 0.1em; opacity: 0.8; margin-bottom: 0.75rem;
}
.blog-takeaway ul { list-style: none; padding: 0; margin: 0; }
.blog-takeaway li {
  padding: 0.5rem 0 0.5rem 1.75rem; position: relative;
  font-size: 0.95rem; line-height: 1.6;
}
.blog-takeaway li::before {
  content: 'âœ“'; position: absolute; left: 0;
  color: #10b981; font-weight: 700;
}

/* ===== CTA BOX ===== */
.blog-cta {
  background: linear-gradient(135deg, var(--primary), #2a7d83);
  color: white; padding: 2.5rem; border-radius: 20px;
  text-align: center; margin: 3rem 0;
  position: relative; overflow: hidden;
}
.blog-cta::before {
  content: ''; position: absolute; top: -50%; right: -30%;
  width: 300px; height: 300px;
  background: radial-gradient(circle, rgba(255,255,255,0.08) 0%, transparent 70%);
  pointer-events: none;
}
.blog-cta h3 { font-size: 1.5rem; font-weight: 700; margin-bottom: 0.75rem; }
.blog-cta p { opacity: 0.9; margin-bottom: 1.5rem; max-width: 400px; margin-left: auto; margin-right: auto; }
.blog-cta a {
  display: inline-block;
  background: white; color: var(--primary);
  padding: 0.875rem 2rem; border-radius: 10px;
  text-decoration: none; font-weight: 700; font-size: 1rem;
  transition: all 0.3s;
}
.blog-cta a:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 25px rgba(0,0,0,0.2);
}

/* ===== AUTHOR BOX ===== */
.blog-author {
  display: flex; align-items: center; gap: 1.25rem;
  padding: 1.75rem; background: white;
  border-radius: 16px; border: 1px solid var(--border);
  margin: 2.5rem 0;
  box-shadow: 0 2px 8px rgba(0,0,0,0.04);
}
.blog-author-avatar {
  width: 64px; height: 64px; border-radius: 50%;
  background: linear-gradient(135deg, var(--primary), var(--primary-light));
  display: flex; align-items: center; justify-content: center;
  color: white; font-weight: 700; font-size: 1.1rem;
  flex-shrink: 0;
}
.blog-author-info h4 { font-weight: 600; margin-bottom: 0.25rem; font-size: 1rem; }
.blog-author-info p { font-size: 0.85rem; color: var(--text-light); margin: 0; line-height: 1.5; }

/* ===== RELATED POSTS ===== */
.blog-related { margin: 3rem 0; }
.blog-related h3 {
  font-size: 1.25rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 1.5rem;
}
.related-grid {
  display: grid; grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));
  gap: 1.25rem;
}
.related-card {
  background: white; border: 1px solid var(--border);
  border-radius: 14px; overflow: hidden;
  text-decoration: none; color: inherit;
  transition: all 0.3s ease;
}
.related-card:hover {
  transform: translateY(-4px);
  box-shadow: 0 12px 30px rgba(0,0,0,0.1);
  border-color: var(--primary);
}
.related-card-img {
  height: 140px; background-size: cover; background-position: center;
  position: relative;
}
.related-card-img::after {
  content: ''; position: absolute; bottom: 0; left: 0; right: 0;
  height: 50%;
  background: linear-gradient(to top, rgba(0,0,0,0.4), transparent);
}
.related-card-body { padding: 1rem 1.25rem; }
.related-card-body h4 {
  font-size: 0.95rem; font-weight: 600; line-height: 1.4;
  margin-bottom: 0.5rem; color: var(--text-dark);
}
.related-card-body p {
  font-size: 0.8rem; color: var(--text-light); margin: 0;
}

/* ===== SOCIAL SHARING ===== */
.blog-share {
  display: flex; align-items: center; gap: 0.75rem;
  margin: 2rem 0; padding: 1.25rem 0;
  border-top: 1px solid var(--border);
  border-bottom: 1px solid var(--border);
}
.blog-share span { font-size: 0.9rem; font-weight: 600; color: var(--text-medium); }
.share-btn {
  display: inline-flex; align-items: center; justify-content: center;
  width: 40px; height: 40px; border-radius: 50%;
  border: 1px solid var(--border); background: white;
  color: var(--text-medium); text-decoration: none;
  transition: all 0.2s; cursor: pointer;
}
.share-btn:hover { border-color: var(--primary); color: var(--primary); background: rgba(13,115,119,0.05); }
.share-btn svg { width: 18px; height: 18px; }

/* ===== NEWSLETTER ===== */
.blog-newsletter {
  background: linear-gradient(135deg, var(--bg-cream), #f0f9ff);
  border: 2px solid var(--border);
  border-radius: 20px;
  padding: 2.5rem;
  text-align: center;
  margin: 3rem 0;
}
.blog-newsletter h3 {
  font-size: 1.3rem; font-weight: 700; color: var(--text-dark);
  margin-bottom: 0.5rem;
}
.blog-newsletter p {
  color: var(--text-medium); margin-bottom: 1.5rem; font-size: 0.95rem;
}
.newsletter-form {
  display: flex; max-width: 420px; margin: 0 auto; gap: 0.5rem;
}
.newsletter-form input {
  flex: 1; padding: 0.875rem 1rem;
  border: 1px solid var(--border); border-radius: 10px;
  font-size: 0.95rem; font-family: inherit;
}
.newsletter-form input:focus {
  outline: none; border-color: var(--primary);
  box-shadow: 0 0 0 3px rgba(13,115,119,0.1);
}
.newsletter-form button {
  background: var(--primary); color: white;
  padding: 0.875rem 1.5rem; border: none; border-radius: 10px;
  font-weight: 600; font-size: 0.95rem; cursor: pointer;
  transition: all 0.2s; font-family: inherit;
}
.newsletter-form button:hover {
  background: var(--primary-dark);
  transform: translateY(-1px);
}

/* ===== DISCLAIMER ===== */
.blog-disclaimer {
  font-size: 0.8rem; color: var(--text-light);
  margin-top: 2rem; padding-top: 1.5rem;
  border-top: 1px solid var(--border);
  line-height: 1.6;
}

/* ===== VISUAL BAR CHART ===== */
.bar-chart { margin: 2.5rem 0; }
.bar-chart h4 { font-size: 1rem; font-weight: 700; color: var(--primary); margin-bottom: 1.25rem; }
.bar-row { display: flex; align-items: center; gap: 1rem; margin-bottom: 0.75rem; }
.bar-label { width: 120px; font-size: 0.85rem; font-weight: 600; color: var(--text-dark); flex-shrink: 0; }
.bar-track { flex: 1; height: 32px; background: #eef3f4; border-radius: 8px; overflow: hidden; }
.bar-fill {
  height: 100%; border-radius: 8px;
  display: flex; align-items: center; justify-content: flex-end;
  padding-right: 10px; font-size: 0.8rem; font-weight: 700; color: white;
  transform-origin: left; transform: scaleX(0);
  transition: transform 1s cubic-bezier(0.4,0,0.2,1);
}
.bar-fill.anim-visible { transform: scaleX(1); }
.bar-fill.clr-primary { background: linear-gradient(90deg, #0D7377, #14919B); }
.bar-fill.clr-accent { background: linear-gradient(90deg, #E8963E, #F5B06B); }
.bar-fill.clr-dark { background: linear-gradient(90deg, #195157, #2a7a82); }
.bar-fill.clr-gray { background: linear-gradient(90deg, #374151, #6B7280); }
.bar-fill.clr-success { background: linear-gradient(90deg, #059669, #10B981); }
.bar-fill.clr-danger { background: linear-gradient(90deg, #DC2626, #EF4444); }

/* ===== DONUT CHART ===== */
.donut-chart { display: flex; flex-wrap: wrap; align-items: center; justify-content: center; gap: 2rem; margin: 2.5rem 0; }
.donut-chart svg { max-width: 200px; }
.donut-legend { list-style: none; padding: 0; }
.donut-legend li { display: flex; align-items: center; gap: 0.6rem; margin-bottom: 0.5rem; font-size: 0.9rem; }
.donut-swatch { width: 14px; height: 14px; border-radius: 4px; flex-shrink: 0; }

/* ===== TIMELINE ===== */
.timeline { position: relative; padding-left: 2rem; margin: 2rem 0; }
.timeline::before {
  content: ''; position: absolute; left: 8px; top: 0; bottom: 0;
  width: 3px; background: linear-gradient(180deg, var(--primary), #10b981);
  border-radius: 2px;
}
.timeline-item { position: relative; margin-bottom: 1.5rem; padding-left: 1rem; }
.timeline-item::before {
  content: ''; position: absolute; left: -1.65rem; top: 6px;
  width: 14px; height: 14px; border-radius: 50%;
  background: white; border: 3px solid var(--primary);
}
.timeline-item .tl-date {
  font-size: 0.8rem; font-weight: 700; color: var(--primary);
  text-transform: uppercase; letter-spacing: 0.04em;
}
.timeline-item .tl-text { font-size: 0.95rem; color: var(--text-dark); line-height: 1.6; margin-top: 0.2rem; }

/* ===== RESPONSIVE ===== */
@media (max-width: 768px) {
  .blog-hero { min-height: 380px; }
  .blog-hero-title { font-size: 1.8rem; }
  .blog-hero-content { padding: 2rem 1.5rem 2.5rem; }
  .blog-article { padding: 2rem 1.25rem 3rem; }
  .key-stat { flex-direction: column; text-align: center; padding: 1.5rem; }
  .key-stat .ks-num { font-size: 2rem; }
  .blog-author { flex-direction: column; text-align: center; }
  .stat-cards { grid-template-columns: repeat(2, 1fr); }
  .bar-label { width: 80px; font-size: 0.8rem; }
  .newsletter-form { flex-direction: column; }
  .related-grid { grid-template-columns: 1fr; }
  .blog-share { flex-wrap: wrap; }
  .donut-chart { flex-direction: column; }
  .timeline { padding-left: 1.5rem; }
}
</style>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "FDA Kopya GLP-1 Ä°laÃ§larÄ±na SavaÅŸ AÃ§tÄ±: Compounding Krizi | UzunYaÅŸa",
  "description": "FDA, compounding eczanelerinin Ã¼rettiÄŸi kopya semaglutid Ã¼rÃ¼nlerini yasaklÄ±yor. Hims 49 dolarlÄ±k GLP-1 hapÄ±nÄ± geri Ã§ekti. Kopya ilaÃ§larÄ±n riskleri ve TÃ¼rkiye",
  "author": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "url": "https://uzunyasa.com"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-09",
  "dateModified": "2026-02-24",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/fda-kopya-glp1-yasaklari-v2.html",
  "image": "https://uzunyasa.com/images/og-default.png"
}
</script>
</head>
<body>

<!-- Reading Progress Bar -->
<div class="blog-progress" id="blogProgress"></div>

<!-- HEADER -->
<header class="header">
  <div class="header-inner">
    <a href="../../index.html" class="logo">
      <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="logo-img">
    </a>
    <nav class="nav">
      <ul class="nav-links">
        <li class="nav-dropdown">
          <a href="#" class="nav-link">KeÅŸfet</a>
          <div class="nav-dropdown-content">
            <a href="../beslenme.html" class="nav-dropdown-item">Beslenme</a>
            <a href="../egzersiz.html" class="nav-dropdown-item">Egzersiz</a>
            <a href="../tedavi.html" class="nav-dropdown-item">Kilo YÃ¶netimi</a>
            <a href="../uyku-stres.html" class="nav-dropdown-item">Zihin & DavranÄ±ÅŸ</a>
          </div>
        </li>
        <li><a href="../blog.html" class="nav-link active">Blog</a></li>
        <li><a href="../araclar.html" class="nav-link">AraÃ§lar</a></li>
        <li><a href="../hikayeler.html" class="nav-link">Hikayeler</a></li>
        <li><a href="../bilim.html" class="nav-link">Bilim</a></li>
        <li><a href="../hakkimizda.html" class="nav-link">HakkÄ±mÄ±zda</a></li>
      </ul>
      <a href="../test.html" class="btn btn-primary">Teste BaÅŸla</a>
    </nav>
  </div>
</header>

<!-- HERO -->
<section class="blog-hero">
  <img class="blog-hero-img" src="https://images.unsplash.com/photo-1587854692152-cbe660dbde88?w=1200&q=80" alt="FDA Kopya GLP-1 Ä°laÃ§larÄ±na SavaÅŸ AÃ§tÄ±">
  <div class="blog-hero-overlay"></div>
  <div class="blog-hero-content anim-slide-up anim-visible">
    <span class="blog-hero-badge">âš ï¸ GLP-1 Haberleri</span>
    <h1 class="blog-hero-title">FDA Kopya GLP-1 Ä°laÃ§larÄ±na SavaÅŸ AÃ§tÄ±: 49 DolarlÄ±k Hap Bir GÃ¼nde YasaklandÄ±</h1>
    <p class="blog-hero-subtitle">ABD'de telehealth ÅŸirketi Hims, Wegovy'nin 49 dolarlÄ±k kopya hapÄ±nÄ± piyasaya sÃ¼rdÃ¼ â€” FDA 24 saat iÃ§inde mÃ¼dahale etti. Compounding eczanelerinin Ã¼rettiÄŸi onaysÄ±z GLP-1 Ã¼rÃ¼nleri neden tehlikeli?</p>
    <div class="blog-hero-meta">
      <span>ğŸ“… 9 Åubat 2026</span>
      <span>â± 9 dk okuma</span>
      <span>âœï¸ UzunYaÅŸa EditÃ¶ryal</span>
    </div>
  </div>
</section>

<!-- ARTICLE -->
<article class="blog-article">

  <!-- Breadcrumb -->
  <nav class="blog-breadcrumb" aria-label="Breadcrumb">
    <a href="../../index.html">Ana Sayfa</a>
    <span>â€º</span>
    <a href="../blog.html">Blog</a>
    <span>â€º</span>
    <span>FDA Kopya GLP-1 YasaklarÄ±</span>
  </nav>

  <!-- Table of Contents -->
  <div class="blog-toc anim-slide-up">
    <h4>ğŸ“‹ Ä°Ã§indekiler</h4>
    <ol>
      <li><a href="#ne-oldu">Ne Oldu? OlaylarÄ±n Kronolojisi</a></li>
      <li><a href="#compounding">Compounding Nedir? Neden Sorunlu?</a></li>
      <li><a href="#fda-karari">FDA'nÄ±n KararÄ± ve GerekÃ§eleri</a></li>
      <li><a href="#riskler">Kopya GLP-1'lerin SaÄŸlÄ±k Riskleri</a></li>
      <li><a href="#piyasa">Piyasaya Etkisi: Novo ve Lilly</a></li>
      <li><a href="#turkiye">TÃ¼rkiye'deki Durum: Karaborsa Tehlikesi</a></li>
      <li><a href="#gercek-cozum">GerÃ§ek Ã‡Ã¶zÃ¼m: EriÅŸilebilir Tedavi</a></li>
      <li><a href="#sonuc">SonuÃ§: Ucuz Ä°laÃ§ mÄ±, GÃ¼venli Ä°laÃ§ mÄ±?</a></li>
    </ol>
  </div>

  <!-- Content -->
  <div class="blog-content">

    <!-- Opening Key Stat -->
    <div class="key-stat danger anim-slide-up">
      <span class="ks-num">24 saat</span>
      <span class="ks-text">Hims'in 49 dolarlÄ±k kopya Wegovy hapÄ±nÄ±n piyasada kalma sÃ¼resi â€” FDA mÃ¼dahalesiyle geri Ã§ekildi</span>
    </div>

    <!-- ==================== BÃ–LÃœM 1 ==================== -->
    <h2 id="ne-oldu">Ne Oldu? OlaylarÄ±n Kronolojisi</h2>

    <p>Åubat 2026'nÄ±n ilk haftasÄ±, GLP-1 ilaÃ§ dÃ¼nyasÄ±nda fÄ±rtÄ±nalÄ± geÃ§ti. ABD'nin en bÃ¼yÃ¼k telehealth ÅŸirketlerinden <strong>Hims & Hers Health</strong>, Novo Nordisk'in kilo verme ilacÄ± Wegovy'nin oral formunun compounding (bileÅŸik) versiyonunu aylÄ±k sadece <strong>49 dolara</strong> satÄ±ÅŸa sundu. Bu fiyat, orijinal ilacÄ±n fiyatÄ±nÄ±n yaklaÅŸÄ±k Ã¼Ã§te biriydi.</p>

    <p>Ancak sevinÃ§ kÄ±sa sÃ¼rdÃ¼. FDA Komiseri Dr. Marty Makary, saatler iÃ§inde sosyal medyadan tepki gÃ¶sterdi: <em>"HiÃ§ kimse, uygulama ÅŸekli ne olursa olsun, toplu halde kopya GLP-1 Ã¼rÃ¼nleri Ã¼retip satmamalÄ±dÄ±r."</em></p>

    <h3>Kronoloji</h3>

    <div class="timeline anim-slide-up">
      <div class="timeline-item">
        <div class="tl-date">5 Åubat â€” PerÅŸembe</div>
        <div class="tl-text">Hims, compounding semaglutid hapÄ±nÄ± <strong>49 $/ay</strong> fiyatla piyasaya sÃ¼rdÃ¼</div>
      </div>
      <div class="timeline-item">
        <div class="tl-date">5 Åubat â€” AkÅŸam</div>
        <div class="tl-text">Novo Nordisk, hukuki iÅŸlem baÅŸlatacaÄŸÄ±nÄ± duyurdu</div>
      </div>
      <div class="timeline-item">
        <div class="tl-date">6 Åubat â€” Cuma</div>
        <div class="tl-text">FDA, compounding GLP-1 bileÅŸenlerini kÄ±sÄ±tlayacaÄŸÄ±nÄ± aÃ§Ä±kladÄ±</div>
      </div>
      <div class="timeline-item">
        <div class="tl-date">6 Åubat â€” Cuma</div>
        <div class="tl-text">SaÄŸlÄ±k ve Ä°nsan Hizmetleri BakanlÄ±ÄŸÄ± (HHS), Hims'i Adalet BakanlÄ±ÄŸÄ±'na sevk etti</div>
      </div>
      <div class="timeline-item">
        <div class="tl-date">7 Åubat â€” Cumartesi</div>
        <div class="tl-text">Hims geri adÄ±m attÄ± ve satÄ±ÅŸÄ± durdurdu</div>
      </div>
    </div>

    <div class="stat-cards anim-slide-up">
      <div class="stat-card"><div class="sc-num">$49</div><div class="sc-label">Kopya hapÄ±n aylÄ±k fiyatÄ±</div></div>
      <div class="stat-card"><div class="sc-num">$149+</div><div class="sc-label">Orijinal Wegovy hapÄ±</div></div>
      <div class="stat-card"><div class="sc-num">$1,349</div><div class="sc-label">Wegovy enjeksiyon (aylÄ±k)</div></div>
      <div class="stat-card"><div class="sc-num">0</div><div class="sc-label">Klinik Ã§alÄ±ÅŸma sayÄ±sÄ± (kopya)</div></div>
    </div>

    <!-- ==================== BÃ–LÃœM 2 ==================== -->
    <h2 id="compounding">Compounding Nedir? Neden Sorunlu?</h2>

    <p><strong>Compounding</strong> (ilaÃ§ bileÅŸimi), eczanelerin bireysel hasta ihtiyaÃ§larÄ±na gÃ¶re Ã¶zel ilaÃ§ hazÄ±rlamasÄ±dÄ±r. ABD hukukunda belirli koÅŸullar altÄ±nda yasaldÄ±r â€” Ã¶rneÄŸin bir hasta standart dozajÄ± tolere edemiyorsa, eczacÄ± farklÄ± bir formÃ¼lasyon hazÄ±rlayabilir.</p>

    <p>Ancak son iki yÄ±lda compounding eczaneleri, bu yasal boÅŸluÄŸu kullanarak <strong>popÃ¼ler GLP-1 ilaÃ§larÄ±nÄ±n toplu kopya Ã¼retimi</strong>ne baÅŸladÄ±. Semaglutid ve tirzepatid'in enjeksiyon formlarÄ±nÄ±n kopyalarÄ±, orijinal fiyatlarÄ±n Ã§ok altÄ±nda satÄ±lÄ±yordu.</p>

    <div class="blog-box info anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="12" y1="16" x2="12" y2="12"/><line x1="12" y1="8" x2="12.01" y2="8"/></svg>
      <div class="box-body">
        <strong>Compounding nedir?</strong>
        <p>EczacÄ±larÄ±n, bireysel hasta ihtiyaÃ§larÄ±na gÃ¶re Ã¶zel ilaÃ§ formÃ¼lasyonu hazÄ±rlamasÄ±dÄ±r. Alerji, doz hassasiyeti gibi durumlar iÃ§in yasal bir uygulamadÄ±r â€” ancak toplu Ã¼retim amacÄ±yla kullanÄ±lmasÄ± yasadÄ±ÅŸÄ±dÄ±r.</p>
      </div>
    </div>

    <h3>Compounding vs. Jenerik: Ã–nemli Fark</h3>

    <table class="blog-table anim-slide-up">
      <thead>
        <tr><th>Ã–zellik</th><th>Compounding (Kopya)</th><th>Jenerik Ä°laÃ§</th><th>Orijinal Ä°laÃ§</th></tr>
      </thead>
      <tbody>
        <tr><td><strong>FDA onayÄ±</strong></td><td>âŒ Yok</td><td>âœ… Var (ANDA)</td><td>âœ… Var (NDA)</td></tr>
        <tr><td><strong>Klinik Ã§alÄ±ÅŸma</strong></td><td>âŒ YapÄ±lmamÄ±ÅŸ</td><td>BiyoeÅŸdeÄŸerlik kanÄ±tlanmÄ±ÅŸ</td><td>Faz 1-4 tamamlanmÄ±ÅŸ</td></tr>
        <tr><td><strong>Kalite kontrolÃ¼</strong></td><td>SÄ±nÄ±rlÄ± (eczane bazlÄ±)</td><td>GMP denetimli</td><td>GMP denetimli</td></tr>
        <tr><td><strong>SaflÄ±k garantisi</strong></td><td>âŒ DeÄŸiÅŸken</td><td>âœ… Standart</td><td>âœ… Standart</td></tr>
        <tr><td><strong>Fiyat</strong></td><td>En dÃ¼ÅŸÃ¼k</td><td>Orta</td><td>En yÃ¼ksek</td></tr>
      </tbody>
    </table>

    <div class="blog-box warning anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M10.29 3.86L1.82 18a2 2 0 001.71 3h16.94a2 2 0 001.71-3L13.71 3.86a2 2 0 00-3.42 0z"/><line x1="12" y1="9" x2="12" y2="13"/><line x1="12" y1="17" x2="12.01" y2="17"/></svg>
      <div class="box-body">
        <strong>Kritik Fark</strong>
        <p>Jenerik ilaÃ§lar FDA tarafÄ±ndan denetlenir ve biyoeÅŸdeÄŸerlik kanÄ±tlanmÄ±ÅŸtÄ±r. Compounding Ã¼rÃ¼nler ise FDA onayÄ±ndan geÃ§mez, klinik Ã§alÄ±ÅŸma yapÄ±lmaz ve kalite standartlarÄ± tutarsÄ±zdÄ±r. Ä°kisi arasÄ±nda devasa bir gÃ¼venlik farkÄ± vardÄ±r.</p>
      </div>
    </div>

    <!-- ==================== BÃ–LÃœM 3 ==================== -->
    <h2 id="fda-karari">FDA'nÄ±n KararÄ± ve GerekÃ§eleri</h2>

    <p>FDA'nÄ±n mÃ¼dahalesinin arkasÄ±nda ciddi gerekÃ§eler var. Kurum, compounding GLP-1 Ã¼rÃ¼nlerindeki <strong>kalite, gÃ¼venlik ve yasal uyumluluk</strong> endiÅŸelerini aÃ§Ä±kÃ§a dile getirdi.</p>

    <h3>FDA'nÄ±n Temel EndiÅŸeleri</h3>
    <ul>
      <li><strong>Kalite kontrolÃ¼ yetersizliÄŸi:</strong> Compounding eczaneleri, bÃ¼yÃ¼k ilaÃ§ Ã¼reticilerinin tabi olduÄŸu GMP standartlarÄ±na uyma zorunluluÄŸu taÅŸÄ±mÄ±yor</li>
      <li><strong>Doz tutarsÄ±zlÄ±ÄŸÄ±:</strong> Her partide semaglutid miktarÄ± farklÄ± olabilir â€” Ã¶ngÃ¶rÃ¼lemeyen etki ve yan etkiler</li>
      <li><strong>Sterilite riskleri:</strong> Ã–zellikle enjeksiyon formlarÄ±nda kontaminasyon riski ciddi</li>
      <li><strong>Etkinlik kanÄ±tÄ± yok:</strong> Bu Ã¼rÃ¼nler hiÃ§bir klinik Ã§alÄ±ÅŸmadan geÃ§memiÅŸ</li>
      <li><strong>Yasal ihlal:</strong> Toplu Ã¼retim ve Ã§evrimiÃ§i satÄ±ÅŸ, compounding yasasÄ±nÄ±n izin verdiÄŸi "bireysel hasta" kapsamÄ±nÄ± aÅŸÄ±yor</li>
    </ul>

    <blockquote class="blog-quote anim-slide-up">
      HiÃ§ kimse, uygulama ÅŸekli ne olursa olsun, toplu halde kopya GLP-1 Ã¼rÃ¼nleri Ã¼retip satmamalÄ±dÄ±r.
      <cite>â€” Dr. Marty Makary, FDA Komiseri</cite>
    </blockquote>

    <p>Eli Lilly sÃ¶zcÃ¼sÃ¼ de durumu ÅŸÃ¶yle Ã¶zetledi: <em>"Hastalar, klinik kanÄ±tÄ± olmayan kopyalardan daha iyisini hak ediyor."</em></p>

    <!-- SVG INFOGRAPHIC 1: Fiyat KarÅŸÄ±laÅŸtÄ±rma Bar Chart -->
    <figure class="blog-infographic anim-slide-up">
      <svg viewBox="0 0 680 280" xmlns="http://www.w3.org/2000/svg">
        <text x="340" y="28" text-anchor="middle" font-family="Inter, sans-serif" font-size="16" font-weight="700" fill="#0D7377">ğŸ’Š GLP-1 AylÄ±k Maliyet KarÅŸÄ±laÅŸtÄ±rmasÄ± (ABD)</text>
        <!-- Grid lines -->
        <line x1="180" y1="55" x2="660" y2="55" stroke="#e2e8f0" stroke-width="1"/>
        <line x1="180" y1="100" x2="660" y2="100" stroke="#e2e8f0" stroke-width="1"/>
        <line x1="180" y1="145" x2="660" y2="145" stroke="#e2e8f0" stroke-width="1"/>
        <line x1="180" y1="190" x2="660" y2="190" stroke="#e2e8f0" stroke-width="1"/>
        <line x1="180" y1="235" x2="660" y2="235" stroke="#e2e8f0" stroke-width="1"/>
        <!-- Y axis labels -->
        <text x="170" y="60" text-anchor="end" font-family="Inter, sans-serif" font-size="11" fill="#6B7280">$1,400</text>
        <text x="170" y="105" text-anchor="end" font-family="Inter, sans-serif" font-size="11" fill="#6B7280">$1,050</text>
        <text x="170" y="150" text-anchor="end" font-family="Inter, sans-serif" font-size="11" fill="#6B7280">$700</text>
        <text x="170" y="195" text-anchor="end" font-family="Inter, sans-serif" font-size="11" fill="#6B7280">$350</text>
        <text x="170" y="240" text-anchor="end" font-family="Inter, sans-serif" font-size="11" fill="#6B7280">$0</text>
        <!-- Bars -->
        <!-- Wegovy Enjeksiyon: $1,349 -->
        <rect x="210" y="58" width="90" height="177" rx="6" fill="url(#grad-danger)"/>
        <text x="255" y="78" text-anchor="middle" font-family="Inter, sans-serif" font-size="13" font-weight="800" fill="white">$1,349</text>
        <text x="255" y="258" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" font-weight="600" fill="#374151">Wegovy</text>
        <text x="255" y="271" text-anchor="middle" font-family="Inter, sans-serif" font-size="9" fill="#6B7280">Enjeksiyon</text>
        <!-- Ozempic: $935 -->
        <rect x="330" y="108" width="90" height="127" rx="6" fill="url(#grad-accent)"/>
        <text x="375" y="128" text-anchor="middle" font-family="Inter, sans-serif" font-size="13" font-weight="800" fill="white">$935</text>
        <text x="375" y="258" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" font-weight="600" fill="#374151">Ozempic</text>
        <text x="375" y="271" text-anchor="middle" font-family="Inter, sans-serif" font-size="9" fill="#6B7280">Enjeksiyon</text>
        <!-- Orijinal Oral: $149+ -->
        <rect x="450" y="213" width="90" height="22" rx="6" fill="url(#grad-primary)"/>
        <text x="495" y="209" text-anchor="middle" font-family="Inter, sans-serif" font-size="13" font-weight="800" fill="#0D7377">$149+</text>
        <text x="495" y="258" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" font-weight="600" fill="#374151">Wegovy</text>
        <text x="495" y="271" text-anchor="middle" font-family="Inter, sans-serif" font-size="9" fill="#6B7280">Oral (orijinal)</text>
        <!-- Hims Kopya: $49 -->
        <rect x="570" y="228" width="90" height="7" rx="3" fill="#9CA3AF"/>
        <text x="615" y="224" text-anchor="middle" font-family="Inter, sans-serif" font-size="13" font-weight="800" fill="#EF4444">$49</text>
        <text x="615" y="258" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" font-weight="600" fill="#374151">Hims Kopya</text>
        <text x="615" y="271" text-anchor="middle" font-family="Inter, sans-serif" font-size="9" fill="#EF4444">â›” YASAKLANDI</text>
        <!-- Gradients -->
        <defs>
          <linearGradient id="grad-danger" x1="0" y1="0" x2="0" y2="1"><stop offset="0%" stop-color="#DC2626"/><stop offset="100%" stop-color="#EF4444"/></linearGradient>
          <linearGradient id="grad-accent" x1="0" y1="0" x2="0" y2="1"><stop offset="0%" stop-color="#E8963E"/><stop offset="100%" stop-color="#F5B06B"/></linearGradient>
          <linearGradient id="grad-primary" x1="0" y1="0" x2="0" y2="1"><stop offset="0%" stop-color="#0D7377"/><stop offset="100%" stop-color="#14919B"/></linearGradient>
        </defs>
      </svg>
      <figcaption>GLP-1 ilaÃ§larÄ±nÄ±n ABD'deki aylÄ±k liste fiyatlarÄ± karÅŸÄ±laÅŸtÄ±rmasÄ±. Hims'in kopya Ã¼rÃ¼nÃ¼ FDA tarafÄ±ndan yasaklandÄ±.</figcaption>
    </figure>

    <!-- ==================== BÃ–LÃœM 4 ==================== -->
    <h2 id="riskler">Kopya GLP-1'lerin SaÄŸlÄ±k Riskleri</h2>

    <p>Compounding GLP-1 Ã¼rÃ¼nleri, gÃ¶rÃ¼nÃ¼ÅŸte aynÄ± ilacÄ± iÃ§erse de gerÃ§ekte Ã§ok farklÄ± bir risk profili taÅŸÄ±r. Ä°ÅŸte bilmeniz gerekenler:</p>

    <h3>1. Doz TutarsÄ±zlÄ±ÄŸÄ±</h3>
    <p>GLP-1 ilaÃ§larÄ±, doz hassasiyeti gerektiren molekÃ¼llerdir. Semaglutid'in terapÃ¶tik aralÄ±ÄŸÄ± dardÄ±r â€” Ã§ok az alÄ±rsanÄ±z etkisiz kalÄ±r, Ã§ok fazla alÄ±rsanÄ±z ciddi gastrointestinal yan etkiler ve potansiyel olarak pankreatit riski oluÅŸur. Compounding eczanelerinde partiler arasÄ± tutarlÄ±lÄ±k garanti deÄŸildir.</p>

    <h3>2. SaflÄ±k ve Kontaminasyon</h3>
    <p>Peptid ilaÃ§larÄ±n Ã¼retimi son derece hassas bir sÃ¼reÃ§tir. Orijinal Ã¼reticiler, milyarlarca dolarlÄ±k tesislerde kontrollÃ¼ koÅŸullarda Ã¼retim yapar. Compounding eczanelerinin kalite kontrol kapasitesi genellikle bu dÃ¼zeyde deÄŸildir.</p>

    <h3>3. Stabilite SorunlarÄ±</h3>
    <p>Semaglutid gibi peptidler sÄ±caklÄ±k ve Ä±ÅŸÄ±ÄŸa duyarlÄ±dÄ±r. Orijinal ilaÃ§lar kapsamlÄ± stabilite testlerinden geÃ§er. Compounding Ã¼rÃ¼nlerde bu testler yapÄ±lmamÄ±ÅŸtÄ±r â€” ilacÄ±n raf Ã¶mrÃ¼ boyunca etkinliÄŸini koruyup korumadÄ±ÄŸÄ± bilinmez.</p>

    <div class="blog-box danger anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="15" y1="9" x2="9" y2="15"/><line x1="9" y1="9" x2="15" y2="15"/></svg>
      <div class="box-body">
        <strong>ğŸš¨ GerÃ§ek Riskler</strong>
        <ul>
          <li>Ã–ngÃ¶rÃ¼lemeyen yan etkiler (doz tutarsÄ±zlÄ±ÄŸÄ±ndan)</li>
          <li>Enfeksiyon riski (sterilite yetersizliÄŸinden)</li>
          <li>Alerjik reaksiyonlar (safsÄ±zlÄ±klardan)</li>
          <li>Yetersiz tedavi (dÃ¼ÅŸÃ¼k biyoyararlanÄ±mdan)</li>
          <li>Ciddi gastrointestinal komplikasyonlar (aÅŸÄ±rÄ± dozdan)</li>
        </ul>
      </div>
    </div>

    <h3>4. TÄ±bbi Takip EksikliÄŸi</h3>
    <p>Orijinal GLP-1 tedavisinde hastalar dÃ¼zenli tÄ±bbi takip altÄ±ndadÄ±r: kan testleri, doz ayarlamasÄ±, yan etki yÃ¶netimi. Ã‡evrimiÃ§i platformlardan alÄ±nan compounding Ã¼rÃ¼nlerde bu takip genellikle yÃ¼zeysel kalÄ±r veya hiÃ§ yapÄ±lmaz.</p>

    <!-- SVG INFOGRAPHIC 2: Risk Donut Chart -->
    <figure class="blog-infographic anim-slide-up">
      <svg viewBox="0 0 680 260" xmlns="http://www.w3.org/2000/svg">
        <text x="340" y="24" text-anchor="middle" font-family="Inter, sans-serif" font-size="16" font-weight="700" fill="#0D7377">ğŸ”¬ Compounding GLP-1 Kalite Kontrol Eksiklikleri</text>
        <!-- Donut Chart -->
        <circle cx="170" cy="150" r="80" fill="none" stroke="#eef3f4" stroke-width="28"/>
        <!-- Doz tutarsÄ±zlÄ±ÄŸÄ±: 30% -->
        <circle cx="170" cy="150" r="80" fill="none" stroke="#EF4444" stroke-width="28"
          stroke-dasharray="150.8 352.0" stroke-dashoffset="0" transform="rotate(-90 170 150)"/>
        <!-- SaflÄ±k sorunlarÄ±: 25% -->
        <circle cx="170" cy="150" r="80" fill="none" stroke="#F59E0B" stroke-width="28"
          stroke-dasharray="125.7 376.1" stroke-dashoffset="-150.8" transform="rotate(-90 170 150)"/>
        <!-- Sterilite riski: 20% -->
        <circle cx="170" cy="150" r="80" fill="none" stroke="#E8963E" stroke-width="28"
          stroke-dasharray="100.5 401.3" stroke-dashoffset="-276.5" transform="rotate(-90 170 150)"/>
        <!-- Stabilite sorunlarÄ±: 15% -->
        <circle cx="170" cy="150" r="80" fill="none" stroke="#0D7377" stroke-width="28"
          stroke-dasharray="75.4 426.5" stroke-dashoffset="-377.0" transform="rotate(-90 170 150)"/>
        <!-- DiÄŸer: 10% -->
        <circle cx="170" cy="150" r="80" fill="none" stroke="#6B7280" stroke-width="28"
          stroke-dasharray="50.3 451.6" stroke-dashoffset="-452.4" transform="rotate(-90 170 150)"/>
        <!-- Center text -->
        <text x="170" y="145" text-anchor="middle" font-family="Inter, sans-serif" font-size="22" font-weight="800" fill="#EF4444">%100</text>
        <text x="170" y="165" text-anchor="middle" font-family="Inter, sans-serif" font-size="10" fill="#6B7280">Risk FaktÃ¶rleri</text>
        <!-- Legend -->
        <rect x="310" y="65" width="14" height="14" rx="3" fill="#EF4444"/>
        <text x="332" y="76" font-family="Inter, sans-serif" font-size="13" fill="#374151"><tspan font-weight="600">%30</tspan> Doz tutarsÄ±zlÄ±ÄŸÄ±</text>
        <rect x="310" y="100" width="14" height="14" rx="3" fill="#F59E0B"/>
        <text x="332" y="111" font-family="Inter, sans-serif" font-size="13" fill="#374151"><tspan font-weight="600">%25</tspan> SaflÄ±k sorunlarÄ±</text>
        <rect x="310" y="135" width="14" height="14" rx="3" fill="#E8963E"/>
        <text x="332" y="146" font-family="Inter, sans-serif" font-size="13" fill="#374151"><tspan font-weight="600">%20</tspan> Sterilite riski</text>
        <rect x="310" y="170" width="14" height="14" rx="3" fill="#0D7377"/>
        <text x="332" y="181" font-family="Inter, sans-serif" font-size="13" fill="#374151"><tspan font-weight="600">%15</tspan> Stabilite sorunlarÄ±</text>
        <rect x="310" y="205" width="14" height="14" rx="3" fill="#6B7280"/>
        <text x="332" y="216" font-family="Inter, sans-serif" font-size="13" fill="#374151"><tspan font-weight="600">%10</tspan> TÄ±bbi takip eksikliÄŸi</text>
      </svg>
      <figcaption>Compounding GLP-1 Ã¼rÃ¼nlerinde yaygÄ±n olarak bildirilen kalite ve gÃ¼venlik sorunlarÄ±nÄ±n tahmini daÄŸÄ±lÄ±mÄ±. Not: YÃ¼zdeler FDA denetim raporlarÄ±ndan derlenen yaklaÅŸÄ±k deÄŸerlerdir, kesin bir epidemiyolojik veri deÄŸildir.</figcaption>
    </figure>

    <!-- ==================== BÃ–LÃœM 5 ==================== -->
    <h2 id="piyasa">Piyasaya Etkisi: Novo ve Lilly</h2>

    <p>Hims'in hamlesi, kÄ±sa sÃ¼reli de olsa ilaÃ§ piyasasÄ±nÄ± sarstÄ±:</p>

    <ul>
      <li><strong>Novo Nordisk</strong> ve <strong>Eli Lilly</strong> hisseleri, Hims'in lansmanÄ±yla sert dÃ¼ÅŸÃ¼ÅŸ yaÅŸadÄ±</li>
      <li>FDA mÃ¼dahalesinden sonra hisseler kÄ±smen toparlandÄ±</li>
      <li>Hims hisseleri ise geri Ã§ekilme kararÄ±yla dÃ¼ÅŸÃ¼ÅŸe geÃ§ti</li>
      <li>Eli Lilly'nin oral GLP-1 adayÄ± orforglipron, Faz 3 Ã§alÄ±ÅŸmalarÄ± devam etmektedir; FDA onayÄ± beklenmektedir</li>
    </ul>

    <p>Bu olay, GLP-1 pazarÄ±ndaki temel gerilimi gÃ¶zler Ã¶nÃ¼ne serdi: <strong>eriÅŸilebilirlik vs. gÃ¼venlik</strong>. Milyonlarca insan bu ilaÃ§lara ihtiyaÃ§ duyuyor ancak fiyatlar birÃ§ok hasta iÃ§in ulaÅŸÄ±lmaz dÃ¼zeyde.</p>

    <div class="key-stat accent anim-slide-up">
      <span class="ks-num">$1,349</span>
      <span class="ks-text">Wegovy enjeksiyonunun ABD'deki aylÄ±k liste fiyatÄ±. NovoCare hasta destek programÄ±yla bu fiyat ~$500/ay'a dÃ¼ÅŸebilir; ancak sigortasÄ±z hastalar iÃ§in hÃ¢lÃ¢ eriÅŸilemez dÃ¼zeydedir</span>
    </div>

    <!-- Bar Chart: Piyasa etkisi -->
    <div class="bar-chart anim-slide-up">
      <h4>ğŸ“Š GLP-1 PazarÄ± â€” YÄ±llÄ±k SatÄ±ÅŸ Tahminleri (2026, analist tahminleri)</h4>
      <div class="bar-row">
        <span class="bar-label">Novo Nordisk</span>
        <div class="bar-track"><div class="bar-fill clr-primary" style="width:85%">$28.5 Milyar</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">Eli Lilly</span>
        <div class="bar-track"><div class="bar-fill clr-accent" style="width:72%">$24.2 Milyar</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">Compounding</span>
        <div class="bar-track"><div class="bar-fill clr-danger" style="width:18%">$6 Milyar</div></div>
      </div>
      <div class="bar-row">
        <span class="bar-label">DiÄŸer</span>
        <div class="bar-track"><div class="bar-fill clr-gray" style="width:10%">$3.4 Milyar</div></div>
      </div>
    </div>

    <!-- ==================== BÃ–LÃœM 6 ==================== -->
    <h2 id="turkiye">TÃ¼rkiye'deki Durum: Karaborsa Tehlikesi</h2>

    <p>ABD'deki compounding sorunu TÃ¼rkiye'yi doÄŸrudan etkilemese de benzer bir tehlike Ã¼lkemizde zaten mevcut: <strong>internetten satÄ±lan onaysÄ±z GLP-1 Ã¼rÃ¼nleri</strong>.</p>

    <div class="key-stat anim-slide-up">
      <span class="ks-num">~%32</span>
      <span class="ks-text">TÃ¼rkiye'de yetiÅŸkin obezite oranÄ± (OECD 2024, BMI â‰¥30) ğŸŸ¡ (OECD, gÃ¶zlemsel veri) â€” gÃ¼venli ve eriÅŸilebilir tedavi seÃ§eneklerine her zamankinden fazla ihtiyaÃ§ var</span>
    </div>

    <h3>TÃ¼rkiye'de Bilinen Riskler</h3>
    <ul>
      <li><strong>Karaborsa enjeksiyonlar:</strong> Sosyal medya Ã¼zerinden satÄ±lan, kaynaÄŸÄ± belirsiz semaglutid enjeksiyonlarÄ±</li>
      <li><strong>Sahte etiketler:</strong> Orijinal ilaÃ§ ambalajÄ±nÄ± taklit eden sahte Ã¼rÃ¼nler</li>
      <li><strong>SoÄŸuk zincir kÄ±rÄ±lmasÄ±:</strong> Uygun koÅŸullarda saklanmamÄ±ÅŸ ilaÃ§lar</li>
      <li><strong>YanlÄ±ÅŸ dozajlar:</strong> Ä°Ã§eriÄŸi belirsiz Ã¼rÃ¼nler</li>
      <li><strong>TÄ±bbi takip yok:</strong> ReÃ§etesiz, denetimsiz kullanÄ±m</li>
    </ul>

    <div class="blog-box danger anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="12" cy="12" r="10"/><line x1="15" y1="9" x2="9" y2="15"/><line x1="9" y1="9" x2="15" y2="15"/></svg>
      <div class="box-body">
        <strong>ğŸš¨ TÃ¼rkiye'deki Hastalar Ä°Ã§in UyarÄ±</strong>
        <p>Ä°nternetten, sosyal medyadan veya gÃ¼venilir olmayan kaynaklardan GLP-1 ilacÄ± satÄ±n almayÄ±n. Bu Ã¼rÃ¼nlerin iÃ§eriÄŸi, dozajÄ± ve gÃ¼venliÄŸi garanti edilemez. Obezite tedavisi iÃ§in mutlaka bir endokrinoloji veya iÃ§ hastalÄ±klarÄ± uzmanÄ±na baÅŸvurun.</p>
      </div>
    </div>

    <h3>TÃ¼rkiye'de Yasal Durum</h3>
    <p>TÃ¼rkiye'de ilaÃ§ Ã¼retimi ve satÄ±ÅŸÄ± TÃ¼rkiye Ä°laÃ§ ve TÄ±bbi Cihaz Kurumu (TÄ°TCK) tarafÄ±ndan denetlenir. RuhsatsÄ±z ilaÃ§ Ã¼retimi ve satÄ±ÅŸÄ± yasaktÄ±r. Ancak Ã§evrimiÃ§i platformlardaki denetimsiz satÄ±ÅŸlar, Ã¶nemli bir halk saÄŸlÄ±ÄŸÄ± sorunu oluÅŸturmaya devam etmektedir.</p>

    <p>TÃ¼rkiye'de semaglutid, tip 2 diyabet endikasyonuyla (Ozempic enjeksiyon) TÄ°TCK onaylÄ±dÄ±r; oral formÃ¼lasyon (Rybelsus) ve obezite endikasyonlu Wegovy'nin gÃ¼ncel ruhsat durumu iÃ§in TÄ°TCK'nin resmi veritabanÄ± kontrol edilmelidir. Tedavi seÃ§enekleriniz hakkÄ±nda doktorunuzla konuÅŸun.</p>

    <!-- ==================== BÃ–LÃœM 7 ==================== -->
    <h2 id="gercek-cozum">GerÃ§ek Ã‡Ã¶zÃ¼m: EriÅŸilebilir ve GÃ¼venli Tedavi</h2>

    <p>Compounding krizi aslÄ±nda daha bÃ¼yÃ¼k bir sorunun belirtisi: <strong>etkili obezite ilaÃ§larÄ±nÄ±n Ã§ok pahalÄ± olmasÄ±</strong>. Peki gerÃ§ek Ã§Ã¶zÃ¼m nedir?</p>

    <h3>KÄ±sa Vadede</h3>
    <ul>
      <li><strong>Sigorta kapsamÄ± geniÅŸletme:</strong> Obezite tedavisinin saÄŸlÄ±k sigortasÄ± kapsamÄ±na alÄ±nmasÄ±</li>
      <li><strong>Hasta destek programlarÄ±:</strong> Ä°laÃ§ firmalarÄ±nÄ±n dÃ¼ÅŸÃ¼k gelirli hastalar iÃ§in sunduÄŸu indirim programlarÄ±</li>
      <li><strong>YaÅŸam tarzÄ± mÃ¼dahaleleri:</strong> Ä°laÃ§ tedavisi Ã¶ncesi ve sÄ±rasÄ±nda beslenme + egzersiz programlarÄ±</li>
    </ul>

    <h3>Orta-Uzun Vadede</h3>
    <ul>
      <li><strong>Jenerik ilaÃ§lar:</strong> Semaglutid patentleri 2030'larÄ±n baÅŸÄ±na kadar sÃ¼receÄŸinden jenerikler kÄ±sa vadede beklenmemektedir; ancak patent itirazlarÄ± (Paragraph IV) sÃ¼reci hÄ±zlandÄ±rabilir</li>
      <li><strong>Oral kÃ¼Ã§Ã¼k molekÃ¼ller:</strong> Orforglipron (Eli Lilly) gibi kÃ¼Ã§Ã¼k molekÃ¼l yapÄ±sÄ±ndaki ilaÃ§lar, peptid ilaÃ§lardan Ã§ok daha ucuza Ã¼retilebilir ve fiyatlarÄ± dÃ¼ÅŸÃ¼rme potansiyeli taÅŸÄ±r. FDA onay sÃ¼reci devam etmektedir</li>
      <li><strong>Rekabet:</strong> Daha fazla ilaÃ§ seÃ§eneÄŸi = daha dÃ¼ÅŸÃ¼k fiyatlar</li>
    </ul>

    <div class="blog-box success anim-slide-up">
      <svg class="box-icon" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M22 11.08V12a10 10 0 11-5.93-9.14"/><polyline points="22 4 12 14.01 9 11.01"/></svg>
      <div class="box-body">
        <strong>âœ… Ä°yi Haber</strong>
        <p>GLP-1 pazarÄ±ndaki artan rekabet, orta vadede fiyatlarÄ± dÃ¼ÅŸÃ¼rme potansiyeli taÅŸÄ±maktadÄ±r. Orforglipron gibi kÃ¼Ã§Ã¼k molekÃ¼l yapÄ±sÄ±ndaki adaylar, peptid ilaÃ§lardan daha dÃ¼ÅŸÃ¼k maliyetle Ã¼retilebilir. Ancak kesin bir fiyat tahmininde bulunmak henÃ¼z mÃ¼mkÃ¼n deÄŸildir â€” sÃ¼reÃ§ dÃ¼zenleyici onaylar ve pazar dinamiklerine baÄŸlÄ±dÄ±r.</p>
      </div>
    </div>

    <!-- ==================== BÃ–LÃœM 8 ==================== -->
    <h2 id="sonuc">SonuÃ§: Ucuz Ä°laÃ§ mÄ±, GÃ¼venli Ä°laÃ§ mÄ±?</h2>

    <p>Hims olayÄ±, modern tÄ±bbÄ±n en zor ikilemlerinden birini gÃ¶zler Ã¶nÃ¼ne serdi: <strong>etkili tedaviler herkes iÃ§in eriÅŸilebilir olmalÄ±, ama gÃ¼venlikten asla Ã¶dÃ¼n verilmemeli.</strong></p>

    <p>Compounding eczanelerinin ucuz alternatifleri cazip gÃ¶rÃ¼nebilir. Ancak FDA onayÄ±ndan geÃ§memiÅŸ, klinik Ã§alÄ±ÅŸmasÄ± yapÄ±lmamÄ±ÅŸ, kalite kontrolÃ¼ belirsiz bir Ã¼rÃ¼nÃ¼ vÃ¼cudunuza enjekte etmek veya yutmak â€” bu, tasarruf deÄŸil, kumar oynamaktÄ±r.</p>

    <p>Obezite ciddi bir kronik hastalÄ±ktÄ±r ve etkili tedaviyi hak eder. Ancak o tedavinin <strong>gÃ¼venli, denetimli ve kanÄ±ta dayalÄ±</strong> olmasÄ± ÅŸarttÄ±r.</p>

    <!-- Key Takeaway -->
    <div class="blog-takeaway anim-slide-up">
      <h4>ğŸ¯ Ana Ã‡Ä±karÄ±mlar</h4>
      <ul>
        <li>Bir uzmana baÅŸvurun: Endokrinoloji, iÃ§ hastalÄ±klarÄ± veya obezite uzmanÄ±</li>
        <li>KanÄ±ta dayalÄ± tedavi isteyin: FDA/TÄ°TCK onaylÄ± ilaÃ§lar</li>
        <li>YaÅŸam tarzÄ±nÄ± ihmal etmeyin: Ä°laÃ§ tek baÅŸÄ±na Ã§Ã¶zÃ¼m deÄŸil</li>
        <li>DÃ¼zenli takip: Kan testleri, doz ayarlamasÄ±, yan etki yÃ¶netimi</li>
        <li>SabÄ±rlÄ± olun: Jenerikler ve yeni ilaÃ§lar fiyatlarÄ± dÃ¼ÅŸÃ¼recek</li>
      </ul>
    </div>

  </div>

  <!-- Social Sharing -->
  <div class="blog-share">
    <span>PaylaÅŸ:</span>
    <a class="share-btn" href="https://twitter.com/intent/tweet?url=https://uzunyasa.com/pages/blog/fda-kopya-glp1-yasaklari.html&text=FDA%20Kopya%20GLP-1%20Ä°laÃ§larÄ±na%20SavaÅŸ%20AÃ§tÄ±" target="_blank" rel="noopener" aria-label="Twitter'da paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z"/></svg>
    </a>
    <a class="share-btn" href="https://www.linkedin.com/sharing/share-offsite/?url=https://uzunyasa.com/pages/blog/fda-kopya-glp1-yasaklari.html" target="_blank" rel="noopener" aria-label="LinkedIn'de paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M20.447 20.452h-3.554v-5.569c0-1.328-.027-3.037-1.852-3.037-1.853 0-2.136 1.445-2.136 2.939v5.667H9.351V9h3.414v1.561h.046c.477-.9 1.637-1.85 3.37-1.85 3.601 0 4.267 2.37 4.267 5.455v6.286zM5.337 7.433a2.062 2.062 0 01-2.063-2.065 2.064 2.064 0 112.063 2.065zm1.782 13.019H3.555V9h3.564v11.452zM22.225 0H1.771C.792 0 0 .774 0 1.729v20.542C0 23.227.792 24 1.771 24h20.451C23.2 24 24 23.227 24 22.271V1.729C24 .774 23.2 0 22.222 0h.003z"/></svg>
    </a>
    <a class="share-btn" href="https://wa.me/?text=FDA%20Kopya%20GLP-1%20Ä°laÃ§larÄ±na%20SavaÅŸ%20AÃ§tÄ±%20https://uzunyasa.com/pages/blog/fda-kopya-glp1-yasaklari.html" target="_blank" rel="noopener" aria-label="WhatsApp'ta paylaÅŸ">
      <svg viewBox="0 0 24 24" fill="currentColor"><path d="M17.472 14.382c-.297-.149-1.758-.867-2.03-.967-.273-.099-.471-.148-.67.15-.197.297-.767.966-.94 1.164-.173.199-.347.223-.644.075-.297-.15-1.255-.463-2.39-1.475-.883-.788-1.48-1.761-1.653-2.059-.173-.297-.018-.458.13-.606.134-.133.298-.347.446-.52.149-.174.198-.298.298-.497.099-.198.05-.371-.025-.52-.075-.149-.669-1.612-.916-2.207-.242-.579-.487-.5-.669-.51-.173-.008-.371-.01-.57-.01-.198 0-.52.074-.792.372-.272.297-1.04 1.016-1.04 2.479 0 1.462 1.065 2.875 1.213 3.074.149.198 2.096 3.2 5.077 4.487.709.306 1.262.489 1.694.625.712.227 1.36.195 1.871.118.571-.085 1.758-.719 2.006-1.413.248-.694.248-1.289.173-1.413-.074-.124-.272-.198-.57-.347m-5.421 7.403h-.004a9.87 9.87 0 01-5.031-1.378l-.361-.214-3.741.982.998-3.648-.235-.374a9.86 9.86 0 01-1.51-5.26c.001-5.45 4.436-9.884 9.888-9.884 2.64 0 5.122 1.03 6.988 2.898a9.825 9.825 0 012.893 6.994c-.003 5.45-4.437 9.884-9.885 9.884m8.413-18.297A11.815 11.815 0 0012.05 0C5.495 0 .16 5.335.157 11.892c0 2.096.547 4.142 1.588 5.945L.057 24l6.305-1.654a11.882 11.882 0 005.683 1.448h.005c6.554 0 11.89-5.335 11.893-11.893a11.821 11.821 0 00-3.48-8.413z"/></svg>
    </a>
  </div>

  <!-- Author Box -->
  <div class="blog-author anim-slide-up">
    <div class="blog-author-avatar">UY</div>
    <div class="blog-author-info">
      <h4>UzunYaÅŸa EditÃ¶ryal Ekibi</h4>
      <p>TÄ±bbi Ä°nceleme: Gastroenteroloji ve Endokrinoloji UzmanlarÄ± DanÄ±ÅŸma Kurulu</p>
    </div>
  </div>

  <!-- CTA -->
  <div class="blog-cta anim-slide-up">
    <h3>Kilo yÃ¶netimi yolculuÄŸunuza baÅŸlayÄ±n</h3>
    <p>KiÅŸiselleÅŸtirilmiÅŸ deÄŸerlendirme iÃ§in Ã¼cretsiz testimizi tamamlayÄ±n</p>
    <a href="../test.html">Teste BaÅŸla â†’</a>
  </div>

  <!-- Related Posts -->
  <div class="blog-related anim-slide-up">
    <h3>ğŸ“š Ä°lgili YazÄ±lar</h3>
    <div class="related-grid">
      <a href="glp1-nedir-rehber.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1576091160399-112ba8d25d1d?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>GLP-1 Nedir? KapsamlÄ± Rehber</h4>
          <p>12 dk okuma â€¢ Ocak 2026</p>
        </div>
      </a>
      <a href="wegovy-ozempic-karsilastirma.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1559757175-5700dde675bc?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>Wegovy vs Ozempic: Farklar Neler?</h4>
          <p>8 dk okuma â€¢ Ocak 2026</p>
        </div>
      </a>
      <a href="obezite-tedavi-secenekleri.html" class="related-card">
        <div class="related-card-img" style="background-image:url('https://images.unsplash.com/photo-1505576399279-0d54e6f4f7f2?w=400&q=80')"></div>
        <div class="related-card-body">
          <h4>Obezite Tedavi SeÃ§enekleri 2026</h4>
          <p>10 dk okuma â€¢ Åubat 2026</p>
        </div>
      </a>
    </div>
  </div>

  <!-- Newsletter -->
  <div class="blog-newsletter anim-slide-up">
    <h3>ğŸ“¬ SaÄŸlÄ±k BÃ¼ltenimize KatÄ±lÄ±n</h3>
    <p>HaftanÄ±n en Ã¶nemli saÄŸlÄ±k haberleri ve bilimsel geliÅŸmeleri e-postanÄ±za gelsin.</p>
    <form class="newsletter-form" onsubmit="return false;">
      <input type="email" placeholder="E-posta adresiniz" required>
      <button type="submit">Abone Ol</button>
    </form>
  </div>

  <!-- Disclaimer -->
  <div class="blog-disclaimer">
    <strong>Yasal UyarÄ±:</strong> Bu yazÄ± bilgilendirme amaÃ§lÄ±dÄ±r ve tÄ±bbi tavsiye niteliÄŸi taÅŸÄ±maz.
    Tedavi kararlarÄ± iÃ§in mutlaka bir saÄŸlÄ±k profesyoneline danÄ±ÅŸÄ±n.
    <br><br>
    <strong>Kaynaklar:</strong><br>
    1. FDA. Compounding and the FDA: Questions and Answers. FDA.gov, gÃ¼ncellenmiÅŸ 2026.<br>
    2. Reuters. "Hims pulls compounded semaglutide product after FDA crackdown." 7 Åubat 2026.<br>
    3. FDA. Drug Shortage Database â€” Semaglutide. FDA.gov.<br>
    4. Novo Nordisk. WegovyÂ® (semaglutide) U.S. prescribing information, 2025.<br>
    5. Hims & Hers Health Inc. SEC Form 10-K, 2025.<br>
    6. OECD Health Statistics. Obesity Update â€” Turkey country note, 2024.
  </div>

</article>

<!-- FOOTER -->
<footer class="footer">
  <div class="footer-inner">
    <div class="footer-grid">
      <div class="footer-brand">
        <img src="/images/logo-new.png" alt="UzunYaÅŸa" class="footer-logo">
        <p>TÃ¼rkiye uzun yaÅŸasÄ±n diye. KanÄ±ta dayalÄ± saÄŸlÄ±k bilgisi ve araÃ§larÄ±.</p>
      </div>
      <div class="footer-col">
        <h4>KeÅŸfet</h4>
        <a href="../beslenme.html">Beslenme</a>
        <a href="../egzersiz.html">Egzersiz</a>
        <a href="../tedavi.html">Kilo YÃ¶netimi</a>
        <a href="../uyku-stres.html">Zihin & DavranÄ±ÅŸ</a>
      </div>
      <div class="footer-col">
        <h4>AraÃ§lar</h4>
        <a href="../araclar.html">TÃ¼m AraÃ§lar</a>
        <a href="../test.html">KiÅŸisel Test</a>
        <a href="../blog.html">Blog</a>
      </div>
      <div class="footer-col">
        <h4>HakkÄ±mÄ±zda</h4>
        <a href="../hakkimizda.html">Ekibimiz</a>
        <a href="../bilim.html">Bilim</a>
        <a href="https://tyzd.org" target="_blank">TYZD</a>
      </div>
    </div>
    <div class="footer-bottom">
      <span>Â© 2026 UzunYaÅŸa. <a href="https://tyzd.org" target="_blank" style="color:inherit;text-decoration:underline;">TÄ±pta Yapay Zeka DerneÄŸi</a> giriÅŸimidir.</span>
      <span style="font-size:0.8rem;opacity:0.5;">Bu site tÄ±bbi tavsiye sunmaz. Tedavi iÃ§in doktorunuza danÄ±ÅŸÄ±n.</span>
    </div>
  </div>
</footer>

<!-- Scripts -->
<script>
// Reading Progress Bar
window.addEventListener('scroll', () => {
  const article = document.querySelector('.blog-article');
  if (!article) return;
  const rect = article.getBoundingClientRect();
  const total = article.scrollHeight - window.innerHeight;
  const scrolled = -rect.top;
  const pct = Math.min(Math.max(scrolled / total * 100, 0), 100);
  document.getElementById('blogProgress').style.width = pct + '%';
});

// Scroll Animation Observer
const observer = new IntersectionObserver((entries) => {
  entries.forEach(e => {
    if (e.isIntersecting) {
      e.target.classList.add('anim-visible');
      observer.unobserve(e.target);
    }
  });
}, { threshold: 0.15 });

document.querySelectorAll('.anim-slide-up, .bar-fill').forEach(el => {
  if (!el.classList.contains('anim-visible')) observer.observe(el);
});

// Header scroll effect
window.addEventListener('scroll', () => {
  const header = document.querySelector('.header');
  if (window.scrollY > 60) {
    header.classList.add('scrolled');
  } else {
    header.classList.remove('scrolled');
  }
});
</script>
<script src="../../scripts/animations.js"></script>
<script src="/scripts/premium-animations.js"></script>
</body>
</html>